misoprostol

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Abdominal wall defectssignal6.36 [2.38, 16.96]-1 study3423not evaluable NApptx
All congenital malformations (majors, minors, majors and minors, or unspecified)signal2.64 [1.03, 6.76]-1 study86118not evaluable criticalpptx
Limb reduction defectsharm, weak evidence15.12 [5.53, 41.34]0%2 studies6147not evaluable NApptx
Major congenital malformationsharm, weak evidence2.86 [1.44, 5.65]0%3 studies36388not evaluable criticalpptx
Moebius syndromeharm, weak evidence32.19 [10.54, 98.31]0%2 studies12574not evaluable NApptx
Nervous system anomaliessignal4.23 [1.47, 12.16]-1 study34145not evaluable NApptx
Oro-facial cleftssignal5.74 [1.34, 24.59]-1 study3452not evaluable NApptx
Vascular disruption anomaliesignal22.00 [6.59, 73.42]-1 study9344not evaluable NApptx
5 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)signal3.51 [1.38, 8.91]-1 study20145not evaluable criticalpptx

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)harm, weak evidence2.16 [1.40, 3.34]36%2 studies36296not evaluable criticalpptx
Elective termination of pregnancysignal5.33 [2.93, 9.71]-1 study74236not evaluable criticalpptx
Intrauterine deaths (as a whole)signal2.27 [1.30, 3.97]-1 study4694not evaluable criticalpptx
2 non statistically significant endpoints reported in only one study